Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

bioMérieux HPV test

This article was originally published in The Gray Sheet

Executive Summary

Paris firm launches human papillomavirus (HPV) diagnostic in Europe April 23. The test, which uses NorChip's m-RNA-based Pre-Tect HPV-proofer on bioMérieux's NucliSENS EasyQ platform, is the result of a recently signed license agreement intended to expand the latter firm's footprint in the infectious disease diagnostic market (1"The Gray Sheet" Jan. 22, 2007, p. 21). bioMérieux's molecular diagnostic enables assessment of the virus' oncogenicity, a feature unattainable with viral DNA tests, the firm says. Digene's DNAwithPap is the only FDA-approved test for HPV, the primary cause of cervical cancer. Roche (Amplicor), Gen-Probe (Aptima), Ventana (Inform) and Third Wave Technologies are developing HPV tests...
Advertisement

Related Content

BioMérieux Moves Forward With HPV, Sepsis Diagnostic Agreements
BioMérieux Moves Forward With HPV, Sepsis Diagnostic Agreements
Advertisement
UsernamePublicRestriction

Register

MT024734

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel